FDA-Approved Subcutaneous Injection Guide
Semaglutide Injection Sites
Semaglutide is approved for subcutaneous injection into one of three sites: the abdomen, the thigh, or the upper arm. Both brands of injectable semaglutide list the same three. What most guides flatten is that Ozempic and Wegovy are two separate labels for one molecule, and on injection technique they do not read identically. The rotation wording differs, the devices differ, and one insulin instruction appears on Ozempic's label and not on Wegovy's.
Key Takeaways
- Three approved sites: abdomen, thigh, and upper arm, on both the Ozempic and the Wegovy Prescribing Information
- Rotate every dose: Ozempic frames it as a different site each week when you inject in the same body region; Wegovy says to rotate injection sites with each dose
- Navel clearance: the 2-inch figure comes from the FDA-approved Instructions for Use packaged with the devices, not from the core Prescribing Information
- Six presentations, two brands: Ozempic pens and syringes, Wegovy single-dose pens and syringes, the 4-dose Wegovy FlexTouch, and Wegovy tablets, which involve no injection at all
- Upper arm: listed on both labels. Only the prefilled-syringe Instructions for Use qualify it as a site to use with help from someone else; the pen and FlexTouch versions do not.
- With insulin: Ozempic's Section 2.1 carries an explicit separate-injection and non-adjacency instruction. Wegovy's label does not carry that instruction, and states the combination with insulin has not been evaluated.
- Site reactions: 0.2% of Ozempic-treated patients in its placebo-controlled diabetes trials, and 1.4% of Wegovy-treated patients versus 1% on placebo in its adult weight-reduction trials, each per Section 6.1 of that brand's label
- Never share a pen between people, even with a new needle, per Ozempic Section 5.4 and, for the FlexTouch specifically, Wegovy Section 5.11
3
Approved Sites
Each dose
Rotation Interval
2 inches
From the Navel
6
Presentations Across Both Brands
The 3 Approved Semaglutide Injection Sites
Section 2.1 of the Ozempic Full Prescribing Information states: "Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm." Wegovy's Section 2.1 lists the same three regions for its injectable presentations. Count them and the list closes at three. Anything else you read online, including the buttock or the flank, is outside what either label approves.
Abdomen
The abdominal site is the soft subcutaneous tissue over the belly, not the muscle wall beneath it. It is the site most people reach for, because you can see what you are doing and pinch the tissue with your free hand. Keep the navel clearance described further down, and treat the abdomen as a left and a right side rather than one target.
Thigh
The front of the thigh is the second self-injection site. It suits people who find the abdomen tender or who already use abdominal tissue for something else. Your prescriber or a diabetes educator can point out the exact band that fits your build, which matters more on a lean thigh than on a lean abdomen.
Upper Arm
Whether the arm is restricted depends on your device. Neither Section 2.1 restricts it. Of the eight injection Instructions for Use packaged across the two brands, exactly two carry a qualifier, and both are the prefilled-syringe leaflets: they list the site as the back of the upper arm, only with help from someone else. The other six show the upper arm with no qualifier at all: as text on every Wegovy device including the FlexTouch and the HD, and as an unlabeled body map in the Ozempic pen leaflets. A real labeling restriction, but one that attaches to the syringes rather than to semaglutide.
If you were dispensed syringes, that settles it. On a pen the constraint is the ordinary one: your own arm is awkward to reach and hard to hold steady, which is why most people use it only when someone else administers the dose. Treating it as a caregiver site anyway is our suggestion for pen users, not a labeling requirement. The next section sorts out which device you have.
One further restriction in Wegovy's Section 2.1 applies to the device rather than the site: the Wegovy FlexTouch is not recommended for self-administration by those who are visually impaired.
Log Every Weekly Dose and Site
Model your weekly semaglutide levels and keep a record of which site you used, in one place. Free, no signup.
Pens, Syringes, FlexTouch, or Tablets: Which Semaglutide Do You Have?
The site list is shared. The hardware is not. Counting from Section 3 of each label, there are six presentations across the two brands, and only one of them is a device you reuse. Reading a friend's instructions for the wrong one is a real way to end up confused at the bathroom counter.
- Ozempic single-patient-use pens, with multiple weekly doses. The one device here you keep and reuse, dialing the dose each week. Section 3 lists doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg. If you are on Ozempic, the Ozempic calculator works from these strengths.
- Ozempic single-dose prefilled syringes. 0.25 mg, 0.5 mg, and 1 mg, each used once and discarded. Nothing to dial.
- Wegovy single-dose pens. One pen, one dose, discarded afterward. Section 3 runs these from 0.25 mg through 2.4 mg and includes the 7.2 mg Wegovy HD, which is also a single-dose pen despite being the top strength. There is nothing to dial, which removes a step and also removes a way to get the step wrong. These map to the Wegovy calculator.
- Wegovy FlexTouch, single-patient-use, 4 doses per pen. The only multi-dose Wegovy device, at 2.4 mg per injection from a 9.6 mg/3 mL pen. It is the presentation Wegovy's never-share warning names, and the one not recommended for self-administration if you are visually impaired.
- Wegovy single-dose syringes. 0.25 mg through 2.4 mg, with their own Instructions for Use.
- Wegovy tablets. Oral semaglutide at 1.5 mg, 4 mg, 9 mg, and 25 mg. No needle, no site, no rotation. If this is what you were dispensed, the rest of this guide does not apply to you.
The one to get right: top strength does not mean multi-dose. The 7.2 mg Wegovy HD is a single-dose pen, and treating it as reusable means expecting doses that are not in it.
Check the carton rather than reasoning from the brand name. Whether you dial a dose or not is a property of the presentation you were handed.
Rotating Semaglutide Injection Sites: Two Labels, Slightly Different Wording
Both labels require rotation. They phrase it differently, and the difference is more than stylistic.
Ozempic, Section 2.1
"Instruct patients to use a different injection site each week when injecting in the same body region."
Wegovy, Section 2.1
"Rotate injection sites with each dose."
Ozempic's sentence is conditional and describes what to do when you stay inside one region: move the spot week to week. Wegovy's is unconditional and shorter. In daily use both land in the same place, which is that this week's spot is not last week's spot. The Ozempic wording is more useful if you are the sort of person who wants a rule for staying inside the abdomen indefinitely, because it tells you that doing so is fine as long as the spot moves.
A four-week cycle across four sites, both sides of the abdomen and both thighs, satisfies either instruction with almost no bookkeeping:
Week 1
Left abdomen
Week 2
Right abdomen
Week 3
Left thigh
Week 4
Right thigh
Add the upper arms if someone else administers your dose and the cycle stretches to six weeks. The semaglutide dosing guide covers how the dose itself steps up alongside this.
Injecting Semaglutide With Insulin: What Ozempic's Label Says
This is the point where treating Ozempic and Wegovy as one interchangeable product goes wrong, so the two labels need separating carefully.
Ozempic's Section 2.1 addresses insulin directly: "When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never mix the products. It is acceptable to inject OZEMPIC and insulin in the same body region, but the injections should not be adjacent to each other." Two rules sit inside that. Never draw the two drugs into one syringe. And the requirement is non-adjacency, not full regional separation: sharing the abdomen with your insulin rotation is permitted, as long as the two injections are not next to each other.
Wegovy is a different document. Its label does not carry that separate-injection and non-adjacency instruction, and it gives a reason: the combination with insulin has not been evaluated. What Wegovy's label does address about diabetes is pharmacologic rather than procedural, covering blood glucose monitoring and the hypoglycemia risk of combining Wegovy with insulin or an insulin secretagogue, where reducing the dose of the other drug may be considered.
Read that asymmetry accurately. Wegovy's label does not prohibit anything about injecting alongside insulin, and it does not warn against a shared site. It simply does not give injection-technique instruction on the subject. If you use Wegovy and insulin together, that is a question for your prescriber, because your label is not the document that answers it.
Zone Separation Is a Planning Tip, Not a Label Requirement
Giving each drug its own territory, insulin in the abdomen and semaglutide in the thighs or the reverse, is the simplest way to stay clear of Ozempic's non-adjacency rule without measuring anything week to week. That approach goes further than either label asks. Treat it as planning guidance, not as a restatement of what the manufacturer requires.
Whichever brand you are on, keep both injectables in a single record. Two schedules running at different frequencies is more than most people track reliably from memory.
The 2-Inch Belly-Button Rule and Where It Actually Comes From
The 2-inch clearance is real, FDA-approved text, just not where most people assume. The core Prescribing Information names the abdomen without specifying any distance from the navel. The measurement lives in the Instructions for Use, approved alongside the label rather than inside its numbered sections. All four Wegovy injection leaflets carry it, the FlexTouch giving it as 2 inches (5 cm), and on the Ozempic side it appears in the Prefilled Syringe Instructions for Use.
The Ozempic pen leaflets do not carry it. If you use an Ozempic pen and cannot find the number in yours, that is why. Keep the clearance regardless.
Neither document explains the reason for the distance. The conventional explanation is that tissue immediately around the navel is denser and less forgiving than the surrounding abdomen, but the manufacturer doesn't say so. Measure the clearance the first few times rather than eyeballing it. Two inches is wider than most people guess.
What to Avoid at the Injection Site
Choosing the region is half the decision. The other half is the specific patch of skin, and Novo Nordisk gives its own list. The Wegovy single-dose pen and HD Instructions for Use direct you not to inject where the skin is tender, bruised, red, or hard, and to avoid areas with scars or stretch marks:
- Tender or sore to the touch
- Bruised, from an injury or a previous injection
- Red or visibly irritated
- Hard, including tissue thickened by repeated use
- Scars or stretch marks, which the manufacturer names specifically and which are easy to overlook on the abdomen
- Inside the navel clearance when you are using the abdomen
Thickened tissue at heavily used sites is called lipohypertrophy, and it is found by touch rather than by looking. Neither semaglutide label describes what happens to absorption from that tissue, so there is no manufacturer figure to weigh. Staying off it is the conservative call, and it is what rotation is for in the first place.
Semaglutide is approved for subcutaneous use. Not intramuscular, not intravenous. If you hit muscle you'll usually know from the sting, and that's a thing to raise with your prescriber rather than repeat.
Does the Injection Site Change How Well Semaglutide Works?
Both labels answer this outright, in Section 12.3, with pharmacokinetic data rather than by omission. Ozempic's reads: "Similar exposure is achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm." Wegovy's Section 12.3 reports the same finding. Wegovy then adds the practical corollary in Section 2.1: the time of day and the injection site can be changed without the need for a dosage modification.
Neither label ranks the three sites either, though that is the weaker way of putting it: both manufacturers measured the question and found the sites equivalent on exposure. The claim that the thigh or the stomach outperforms the rest runs against their own data.
So pick on comfort, reach, and what your rotation leaves available this week. The variables actually in your hands are rotating properly, injecting into healthy tissue, and not missing doses.
Semaglutide Injection Site Reactions: What Is Normal, What Is Not
Both labels report a rate in Section 6.1, and they are not the same number. Ozempic reports injection site reactions such as discomfort and redness in 0.2% of Ozempic-treated patients in its placebo-controlled trials. Wegovy reports them in 1.4% of Wegovy-treated patients versus 1% on placebo in its adult weight-reduction trials, listing pruritus, erythema, inflammation, induration, and irritation.
Read those figures with care. They come from different trial programs in different populations, so the gap between them is not a head-to-head finding about the brands. Both make the same practical point: local reactions happen, and they are uncommon.
Usually routine
- A small red bump or raised patch
- Mild itching at the site
- Minor bruising from the needle
- Brief stinging as the dose goes in
Contact your provider
- Redness or warmth that spreads
- Pus or discharge at the site
- Swelling that grows over 24 hours
- Hives or swelling away from the site
- A firm lump that persists between doses
The split above is general injection guidance rather than label text. Everything happening away from the injection site is covered in the semaglutide side effects guide.
How to Inject an Ozempic Pen: Video Demonstration
This Drugs.com demonstration walks the Ozempic pen sequence end to end, including the site check and the navel clearance. Check it against the Instructions for Use packaged with your own device, since the Wegovy pens do not handle the same way.
Video: Drugs.com. "How to use an Ozempic (semaglutide) Pen."
Semaglutide Injection Sites: Frequently Asked Questions
Where is the best place to inject semaglutide?
Semaglutide is approved for subcutaneous injection into the abdomen, the thigh, or the upper arm. Both the Ozempic and the Wegovy labels list those same three regions and instruct rotating between them, and neither names one as better than another. The abdomen and thigh are the two most people use for self-injection.
Does semaglutide work better in the thigh?
No. Section 12.3 of both the Ozempic and the Wegovy Prescribing Information reports that similar exposure is achieved with subcutaneous administration in the abdomen, thigh, or upper arm. The manufacturers measured it and found the three sites equivalent, so site choice is a comfort and logistics decision. What matters clinically is rotating properly and injecting into healthy tissue.
Where should you not inject semaglutide?
The Wegovy single-dose pen and HD Instructions for Use say not to inject where the skin is tender, bruised, red, or hard, and to avoid areas with scars or stretch marks. Stay at least 2 inches from the belly button when using the abdomen. Semaglutide is approved for subcutaneous use only, so it should not go into muscle or a vein.
Is Ozempic's insulin instruction the same as Wegovy's?
No. Ozempic's Section 2.1 instructs giving Ozempic and insulin as separate injections, never mixing the products, and keeping the injections non-adjacent if they share a body region. Wegovy's label carries no equivalent technique instruction and states the combination with insulin has not been evaluated. If you use Wegovy with insulin, plan your sites with your prescriber.
How far from my belly button should I inject?
At least 2 inches. All four Wegovy injection leaflets carry it, the FlexTouch giving it as 2 inches (5 cm), and on the Ozempic side it appears in the Prefilled Syringe Instructions for Use. It is not stated in the numbered sections of the Prescribing Information, which name the abdomen without specifying a clearance, so keep the leaflet that arrives in the box.
Are the Ozempic pen and the Wegovy pen the same device?
No. Ozempic's pen is single-patient-use and holds multiple weekly doses at 0.25 mg to 2 mg. Wegovy's pens are single-dose, from 0.25 mg up to and including the 7.2 mg Wegovy HD. The only multi-dose Wegovy device is the FlexTouch, which holds 4 doses at 2.4 mg. Both brands also come as single-dose syringes, and Wegovy as tablets.
Can I inject semaglutide into my own upper arm?
It depends on your device. Neither Section 2.1 restricts the arm, but the prefilled-syringe Instructions for Use for both brands list it as the back of the upper arm, only with help from someone else. The pen and FlexTouch Instructions for Use carry no such qualifier. On syringes the arm is a caregiver site; on pens it is not restricted, though most people still find it hard to reach unaided.
How often should I rotate my semaglutide injection site?
Every dose. Ozempic's label frames it as using a different site each week when you inject in the same body region. Wegovy's says to rotate injection sites with each dose. Both come to the same practical rule: this week's spot is not last week's spot. A four-site cycle across both sides of the abdomen and both thighs covers a month without any tracking effort.
How common are injection site reactions?
Each brand reports its own rate in Section 6.1. Ozempic gives 0.2% of Ozempic-treated patients in its placebo-controlled diabetes trials. Wegovy gives 1.4% of Wegovy-treated patients versus 1% on placebo in its adult weight-reduction trials. Different trial programs and different populations, so the two figures are not a head-to-head comparison of the brands.
Can I share a pen with someone on the same dose?
No. Ozempic's Section 5.4 warns against sharing an Ozempic pen, and Wegovy's Section 5.11 does the same for the FlexTouch, the multi-dose Wegovy device the warning is written for. Both rule it out even if the needle is changed, because of the risk of passing on blood-borne pathogens. Matching doses does not change that.
Your Dose and Your Sites, One View
Model your weekly semaglutide levels and keep your rotation recorded alongside them. Free, no signup required.
References
- Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use. Full Prescribing Information, Section 2.1 Important Administration Instructions, Section 3 Dosage Forms and Strengths, Section 5.4 Never Share an OZEMPIC Pen Between Patients, Section 6.1 Clinical Trials Experience, Section 12.3 Pharmacokinetics. Revised 05/2026. novo-pi.com/ozempic.pdf
- Novo Nordisk. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets. Full Prescribing Information, Section 2.1 Important Monitoring and Administration Instructions, Section 3 Dosage Forms and Strengths, Section 5.11 Never Share WEGOVY FlexTouch Between Patients, Section 6.1 Clinical Trials Experience, Section 12.3 Pharmacokinetics. Revised 06/2026. novo-pi.com/wegovy.pdf
- Novo Nordisk. OZEMPIC (semaglutide) injection: Prefilled Syringe Instructions for Use. Source of the 2-inch navel clearance and the upper-arm caregiver qualifier on the Ozempic side. novo-pi.com/ozempic.pdf
- Novo Nordisk. WEGOVY (semaglutide) injection: Single-Dose Pen and WEGOVY HD Instructions for Use. Source of the avoid-skin list. Both list the upper arm unqualified. novo-pi.com/wegovy.pdf
- Novo Nordisk. WEGOVY FlexTouch (semaglutide) injection Instructions for Use. Source of the clearance given as 2 inches (5 cm). Lists the upper arms unqualified; does not carry the avoid-skin list. novo-pi.com/wegovy.pdf
- Novo Nordisk. WEGOVY (semaglutide) injection: Prefilled Syringe Instructions for Use. Source of the upper-arm caregiver qualifier on the Wegovy side. novo-pi.com/wegovy.pdf
- Drugs.com. How to use an Ozempic (semaglutide) Pen. Video demonstration. youtube.com
Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Semaglutide is an FDA-approved prescription medication, marketed as Ozempic for type 2 diabetes and as Wegovy for weight management. Do not start, stop, or change your dose, your insulin regimen, or your injection routine without guidance from a licensed clinician. The technique guidance here is drawn from FDA prescribing information and manufacturer patient instructions; always defer to your prescriber and to the Instructions for Use packaged with your own device.